These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 33844022)

  • 1. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
    Mease PJ; McInnes IB; Tam LS; Eaton K; Peterson S; Schubert A; Chakravarty SD; Parackal A; Karyekar CS; Nair S; Boehncke WH; Ritchlin C
    Rheumatology (Oxford); 2021 May; 60(5):2109-2121. PubMed ID: 33844022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.
    Mease PJ; McInnes IB; Tam LS; Rajalingam R; Peterson S; Hassan F; Chakravarty SD; Contré C; Armstrong A; Boehncke WH; Ritchlin C
    Rheumatology (Oxford); 2023 Apr; 62(4):1417-1425. PubMed ID: 36102818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
    Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
    Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: A network meta-analysis.
    Song GG; Lee YH
    Int J Clin Pharmacol Ther; 2021 Jun; 59(6):433-441. PubMed ID: 33860750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.
    Rahman P; Ritchlin CT; Helliwell PS; Boehncke WH; Mease PJ; Gottlieb AB; Kafka S; Kollmeier AP; Hsia EC; Xu XL; Shawi M; Sheng S; Agarwal P; Zhou B; Ramachandran P; Zhuang Y; McInnes IB
    J Rheumatol; 2021 Dec; 48(12):1815-1823. PubMed ID: 33934076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.
    McInnes IB; Sawyer LM; Markus K; LeReun C; Sabry-Grant C; Helliwell PS
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35321874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
    Mease PJ; Gottlieb AB; Ogdie A; McInnes IB; Chakravarty SD; Rampakakis E; Kollmeier A; Xu XL; Shawi M; Lavie F; Kishimoto M; Rahman P
    Clin Rheumatol; 2024 Jan; 43(1):241-249. PubMed ID: 37787903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Ruyssen-Witrand A; Perry R; Watkins C; Braileanu G; Kumar G; Kiri S; Nott D; Liu-Leage S; Hartz S; Sapin C
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32094304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
    Coates LC; Gossec L; Theander E; Bergmans P; Neuhold M; Karyekar CS; Shawi M; Noël W; Schett G; McInnes IB
    Ann Rheum Dis; 2022 Mar; 81(3):359-369. PubMed ID: 34819273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
    Rahman P; Mease PJ; Helliwell PS; Deodhar A; Gossec L; Kavanaugh A; Kollmeier AP; Hsia EC; Zhou B; Lin X; Shawi M; Karyekar CS; Han C
    Arthritis Res Ther; 2021 Jul; 23(1):190. PubMed ID: 34261541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
    Siebert S; Coates LC; Schett G; Raychaudhuri SP; Chen W; Gao S; Seridi L; Chakravarty SD; Shawi M; Lavie F; Sharaf M; Zimmermann M; Kollmeier AP; Xu XL; Rahman P; Mease PJ; Deodhar A
    Arthritis Rheumatol; 2024 Jun; 76(6):894-904. PubMed ID: 38253404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
    Gottlieb AB; McInnes IB; Rahman P; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; Lavie F; Mease PJ
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36828643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
    Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
    Ritchlin CT; Helliwell PS; Boehncke WH; Soriano ER; Hsia EC; Kollmeier AP; Chakravarty SD; Zazzetti F; Subramanian RA; Xu XL; Zuraw QC; Sheng S; Jiang Y; Agarwal P; Zhou B; Zhuang Y; Shawi M; Karyekar CS; Deodhar A
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33568556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Mease PJ; Gladman DD; Merola JF; Nash P; Grieve S; Laliman-Khara V; Willems D; Taieb V; Prickett AR; Coates LC
    Rheumatology (Oxford); 2024 Jul; 63(7):1779-1789. PubMed ID: 38218744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials.
    Thilakarathne P; Schubert A; Peterson S; Noel W; Patel BP; Hassan F
    Rheumatol Ther; 2024 Apr; 11(2):457-474. PubMed ID: 38416392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Chakravarty SD; Xu XL; Subramanian RA; Agarwal P; Sheng S; Jiang Y; Zhou B; Zhuang Y; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2021 Apr; 73(4):604-616. PubMed ID: 33043600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.